MENU
+Compare
XPH
ETF ticker: NYSE ARCA
AS OF
Feb 21 closing price
Price
$44.71
Change
-$0.22 (-0.49%)
Net Assets
163.38M

XPH stock forecast, quote, news & analysis

Category: @Health
XPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for XPH with price predictions
Feb 21, 2025

XPH in +1.54% Uptrend, rising for three consecutive days on February 13, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where XPH advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where XPH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

XPH moved above its 50-day moving average on January 23, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for XPH crossed bullishly above the 50-day moving average on January 29, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 239 cases where XPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XPH as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XPH turned negative on February 14, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XPH broke above its upper Bollinger Band on January 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the SPDR® S&P Pharmaceuticals ETF ETF is 141.53B. The market cap for tickers in the group ranges from 4.35B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is PRGO at 4.35B.

High and low price notable news

The average weekly price growth across all stocks in the SPDR® S&P Pharmaceuticals ETF ETF was -0%. For the same ETF, the average monthly price growth was 0%, and the average quarterly price growth was 2%. MRK experienced the highest price growth at 8%, while ITCI experienced the biggest fall at 1%.

Volume

The average weekly volume growth across all stocks in the SPDR® S&P Pharmaceuticals ETF ETF was 14%. For the same stocks of the ETF, the average monthly volume growth was 20% and the average quarterly volume growth was 120%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 42
P/E Growth Rating: 73
Price Growth Rating: 48
SMR Rating: 64
Profit Risk Rating: 60
Seasonality Score: -61 (-100 ... +100)
View a ticker or compare two or three
XPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com